Erysipelas

An acute infection of the skin caused by species of STREPTOCOCCUS. This disease most frequently affects infants, young children, and the elderly. Characteristics include pink-to-red lesions that spread rapidly and are warm to the touch. The commonest site of involvement is the face.

Networked: 651 relevant articles (38 outcomes, 56 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Cellulitis
2.	Lymphedema (Milroy Disease)
3.	Neoplasms (Cancer)
4.	Abscess
5.	Breast Neoplasms (Breast Cancer)

Experts

1.	Cussler, K: 5 articles (01/2002 - 01/2001)
2.	Rosskopf-Streicher, U: 4 articles (01/2002 - 01/2001)
3.	Sunderkötter, Cord: 3 articles (01/2022 - 01/2006)
4.	Harks, F: 3 articles (07/2015 - 01/2015)
5.	Hoeijmakers, M: 3 articles (07/2015 - 01/2015)
6.	Linder, Adam: 3 articles (05/2014 - 05/2010)
7.	Nagai, Shinya: 3 articles (12/2010 - 07/2007)
8.	To, Ho: 3 articles (12/2010 - 07/2007)
9.	Bernard, P: 3 articles (05/2003 - 03/2001)
10.	Johannes, S: 3 articles (01/2002 - 01/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Erysipelas:

1.	Anti-Bacterial Agents (Antibiotics)IBA 03/01/2001 - "Thus, the first line treatment for all erysipelas must be an antistreptococcal antibiotic. " 01/01/2017 - "Our study showed that prior antibiotics taking and higher sedimentation rate are independent risk factors for local complications of erysipelas. " 08/01/2015 - "Whether the use of PCT levels for early differentiation of erysipelas from DVT reduces unnecessary antibiotic exposure needs to be assessed in an interventional trial. " 06/12/2019 - "As 5.1% and 3.7% of antibiotic prescriptions are made for erysipelas and teeth/gum disease, respectively, we propose to add these indications when assessing antibiotic prescribing quality in OOH primary care." 01/01/2019 - "Prevention of erysipelas relapses therefore demands for novel antibiotic strategies capable of eradicating intracellular streptococcal persistence."
2.	VaccinesIBA 12/01/2010 - "Taken together, these results demonstrate for the first time the striking protective efficacy of the α-helical domain-mediated immunization in both mice and pigs, thereby highlighting its utility as the most promising candidate for the development of a safe and effective vaccine against erysipelas." 01/01/2020 - "While commercially produced erysipelas vaccines appear to provide good protection against clinical disease, in recent years there has been an increase in perceived vaccine failures in farmed animals, especially in organic outdoor operations. " 07/31/2015 - "Safety and efficacy of a new octavalent combined Erysipelas, Parvo and Leptospira vaccine in gilts against Leptospira interrogans serovar Pomona associated disease and foetal death." 03/01/2014 - "This study investigated the prevalence, and characteristics of Erysipelothrix rhusiopathiae isolates in Japan from 2008 to 2010 and assessed the efficacy of current commercial erysipelas vaccines. " 06/06/2001 - "In conclusion, vaccination trials in mice indicate that commercial serotype 2 swine Erysipelothrix vaccines induce protection against erysipelas caused by dolphin pathogenic isolates."
3.	Penicillins (Penicillin)FDA Link 07/01/2004 - "Intramuscular penicillin should be considered an effective and well-tolerated treatment of erysipelas in adult patients." 07/01/2004 - "The objective of the study was to evaluate the efficacy of intramuscular penicillin: mixture of benzyl penicillin and procain penicillin (2 MU x 2 times daily) and intravenous benzyl penicillin (4 MU x 6 times daily) in the treatment of hospitalized adult patients with erysipelas. " 01/01/1951 - "The efficacy of penicillin and 2-sulfanilamido-5-methyl-1,3,4, thiodiazole (lucosil) in the treatment of erysipelas." 07/01/2004 - "Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study." 02/01/2020 - "Erysipelas can be managed with oral or intravenous penicillin. "
4.	Penicillin G (Benzylpenicillin)FDA LinkGeneric 01/01/2006 - "Penicillin G or V are the first line treatment for erysipelas. " 04/01/2005 - "[Penicillin G and erysipelas--still being used?]." 01/01/2003 - "This is not justified as in fact erysipelas is usually sensitive to penicillin G. " 02/20/1987 - "When treatment with penicillin G is not successful, erysipelas caused by staphylococci has to be considered. " 03/01/2001 - "The reference therapy for erysipelas is penicillin G given intravenously. "
5.	Sodium SeleniteIBA 05/01/1998 - "Sodium selenite as prophylaxis against erysipelas in secondary lymphedema." 05/01/1998 - "In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymphedema, with special reference to the development of the incidence of erysipelas. " 09/01/2016 - "Treatment with sodium selenite lowers reactive oxygen species (ROS) production, causes a spontaneous reduction in lymphedema volume, increases the efficacy of physical therapy for lymphedema, and reduces the incidence of erysipelas infections in patients with chronic lymphedema. "
6.	RoxithromycinIBA 08/01/1992 - "Oral roxithromycin can thus be considered an effective and well-tolerated treatment for erysipelas in adult hospitalized patients." 01/01/1996 - "We recently demonstrated that oral roxithromycin is as effective as intravenous penicillin G in adults with erysipelas. " 08/01/1992 - "Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study."
7.	AntigensIBA 08/01/2001 - "Results of the collaborative study indicate that the candidate batch of erysipelas ELISA coating antigen is suitable to act as a Ph. Eur. " 08/01/2001 - "To that end, 13 laboratories from 9 European countries, including 5 manufacturers, 7 authorities and EDQM, have taken part in a collaborative study to evaluate the suitability of a candidate reference preparation of erysipelas coating antigen for ELISA as a European Pharmacopoeia Biological Reference Preparation (Ph. Eur. " 08/01/2001 - "Collaborative study for the establishment of erysipelas ELISA coating antigen. " 01/01/2017 - "The establishment of character and dynamics of migration activity of leukocytes on partial genes antigens S.pyogenes in screening test of cellular migration can be used in diagnostics of various forms of erysipelas, evaluation of expression of intoxication, prognosis of complications and relapses. " 04/01/2008 - "[T-cell responsiveness to specific group A streptococcus antigens in patients with recurrent erysipelas]."
8.	Bacterial VaccinesIBA 12/01/1989 - "Of 76 isolates used for challenge in the cross-protection study, 29 (38.2%) killed greater than 40% of mice immunized with an erysipelas bacterin marketed in Indonesia. " 10/01/1954 - "Field trials of a bacterin for the control of erysipelas in turkeys." 10/01/1988 - "Turkeys vaccinated subcutaneously with a commercial bacterin, the current immunoprophylactic agent for erysipelas control, were protected against challenge. " 03/01/1978 - "One group from each diet treatment was given a single injection of an erysipelas bacterin, and 21 days later all pigs were given a challenge inoculum of virulent Erysipelothrix rhusiopathiae organisms. " 04/01/1975 - "Antibody activity against Erysipelothrix insidiosa was measured in 15 porpoises which had undergone a series of vaccinations, at 6 month intervals, with erysipelas bacterin. "
9.	CytokinesIBA 01/01/2018 - "In the future we plan to study pharmacological correction of shifts in cytokine blood profile with drugs with immunomodulating properties in patients with complicated erysipelas." 01/01/2018 - "The cytokine blood profile in patients with complicated erysipelas was investigated. " 01/01/2018 - "INDEXES OF CYTOKINE PROFILE OF BLOOD IN PATIENTS WITH COMPLICATED ERYSIPELAS." 01/01/2017 - "Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients." 01/01/2016 - " Marked changes in the indices of phagocytic activity of monocytes (PHAM) and the cytokine profile in patients with erysipelas were note. "
10.	MacrolidesIBA 03/01/2001 - "The use of macrolides and stretogramins is an alternative after the exclusion of severe forms of erysipelas. " 01/01/1996 - "Overall effectiveness was comparable with that reported for penicillin G or macrolides in erysipelas." 10/01/2016 - "The efficacy of treatment of cellulitis or erysipelas was similar with a beta-lactam [27/221 (12 %) not cured] and a macrolide or lincosamide [21/241 (9 %) not cured, RR 1.24, 95 % CI 0.72-2.41, p = 0.44]. " 10/01/2016 - "We included randomised trials that compared monotherapy with a beta-lactam with monotherapy with a macrolide or lincosamide for cellulitis or erysipelas. " 10/01/2016 - "We conducted a meta-analysis of published trials in which patients with cellulitis or erysipelas were randomised to treatment either with a beta-lactam or with a macrolide or lincosamide. "

Therapies and Procedures

1.	Therapeutics 01/01/1999 - "The present treatment regimen appears to be an effective therapy for prevention of recurrent erysipelas." 07/01/2014 - "The objective of the present study was to evaluate the possibility and effectiveness of the application of general magnetic therapy for the combined treatment and rehabilitation of the patients presenting with hemorrhagic forms of erysipelas. " 08/01/1998 - "The aims of this study were to determine the relationship between skin mechanical properties and changes in dermal water content in patients with erysipelas of the lower leg, and to assess the value of measuring skin elasticity in monitoring the effect of therapy. " 01/01/2021 - "[Diagnosis and therapy of erysipelas: A position paper of the Society Initiative Chronische Wunde (ICW) e. V.]" 01/01/2021 - "In this retrospective analysis it could be shown for the first time that compression therapy does not cause a clinical worsening or trigger a septic clinical picture in patients with acute erysipelas. "
2.	Physical Therapy Modalities (Physical Therapy Technique) 05/01/1998 - "In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymphedema, with special reference to the development of the incidence of erysipelas. " 09/01/2016 - "Treatment with sodium selenite lowers reactive oxygen species (ROS) production, causes a spontaneous reduction in lymphedema volume, increases the efficacy of physical therapy for lymphedema, and reduces the incidence of erysipelas infections in patients with chronic lymphedema. "
3.	Antibiotic Prophylaxis 03/01/2007 - "In a minority of cases, erysipelas recurs despite antibiotic prophylaxis. " 03/01/2007 - "Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies." 01/01/2007 - "Our results showed that erysipelas recurrence has the same risk factors as single episodes and underlines the potential benefit of oral or parenteral antibiotic prophylaxis to prevent recurrences." 01/01/1995 - "Metabolic equilibrium, disinfecting skin areas and antibiotic prophylaxis are urgent steps in the successful treatment of Erysipelas disease." 11/01/1993 - "Only in patients with a high recurrence rate continuous antibiotic prophylaxis against erysipelas is indicated."
4.	Radiotherapy 01/01/2019 - "The mechanism of the occurrence of erysipelas after radiotherapy coincides with its pathophysiology. " 04/01/2017 - " were 30 cases with history of radiation therapy and 23 cases with history of erysipelas recurrent((2.1±3.9)/year). " 01/01/2019 - "Its association with alteration of cellular immunity, also favored by radiotherapy and chemotherapy, can cause the occurrence of erysipelas in these patients. " 02/01/1967 - "[2 cases of cancer improved by erysipelas complication during radiotherapy]." 08/01/2002 - "Between February 93 and December 99, 20 patients among 700 (2.85%) treated for breast cancer in the radiotherapy department of sfax have presented an erysipelas. "
5.	Aftercare (After-Treatment) 01/01/2015 - "Remarkable reduction of occurrence frequency of erysipelas caused by various reasons was showed after treatment. " 11/01/1982 - "Erysipelas developed in a young woman whose condition had been in remission for ten years after treatment of stage IIIA Hodgkin's disease. " 01/01/2005 - "Severe erysipelas after treatment for breast cancer." 08/01/2002 - "Erysipelas after treatment of breast cancer is known but rarely reported. " 04/01/2008 - "These groups were compared with regard to gender, age of onset, age of diagnosis, time interval between disease onset and diagnosis, fever, abdominal pain, arthritis, chest pain, erysipelas-like erythema, edema, amyloidosis, number of attacks per year before and after treatment, consanguinity, severity score, response of colchicines treatment, and family history of FMF and amyloidosis. "